moxifloxacin has been researched along with mefloquine in 6 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (mefloquine) | Trials (mefloquine) | Recent Studies (post-2010) (mefloquine) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 71 | 0 | 66 |
| 3,157 | 552 | 1,690 | 2,212 | 342 | 560 |
| Protein | Taxonomy | moxifloxacin (IC50) | mefloquine (IC50) |
|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 2.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kumari, D; Perveen, S; Sharma, R; Singh, K | 1 |
| Binstock, P; Keating, M; Kontoyiannis, DP; Nannini, EC; Samonis, G | 1 |
| Bermudez, LE; Inderlied, CB; Kolonoski, P; Petrofsky, M; Wu, M; Young, LS | 1 |
| Bermudez, LE; Kolonoski, P; Petrofsky, M; Reynolds, R; Seitz, LE; Wu, M; Young, LS | 1 |
| Babrak, L; Bermudez, LE; Burrows, G; Chinison, JJJ; Danelishvili, L; Hu, J; Morgun, A; Shulzhenko, N | 1 |
2 review(s) available for moxifloxacin and mefloquine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin | 2022 |
4 other study(ies) available for moxifloxacin and mefloquine
| Article | Year |
|---|---|
Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Drug Therapy, Combination; Ethambutol; Fatal Outcome; Fluoroquinolones; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Linezolid; Male; Mefloquine; Middle Aged; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Oxazolidinones; Quinolines | 2002 |
Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antimalarials; Aza Compounds; Clarithromycin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Mefloquine; Mice; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolines | 2003 |
SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Colony Count, Microbial; Drug Interactions; Drug Therapy, Combination; Female; Fluoroquinolones; Liver; Mefloquine; Mice; Mice, Inbred C57BL; Moxifloxacin; Mycobacterium avium-intracellulare Infection; Quinolines; Spleen; Thioacetazone | 2004 |
Mycobacterium tuberculosis Proteome Response to Antituberculosis Compounds Reveals Metabolic "Escape" Pathways That Prolong Bacterial Survival.
Topics: Antitubercular Agents; Diarylquinolines; Fluoroquinolones; Isoniazid; Mefloquine; Moxifloxacin; Mycobacterium tuberculosis; Proteome; Proteomics; Rifampin | 2017 |